| TH, n = 3 | TL, n = 3 | Placebo, n = 3 | ||||||
---|---|---|---|---|---|---|---|---|---|
TH1 | TH2 | TH3 | TL1 | TL2 | TL3 | C1 | C2 | C3 | |
Age (years) | 47 | 32 | 31 | 32 | 38 | 33 | 39 | 34 | 43 |
Sex | Male | Male | Male | Male | Male | Male | Female | Male | Male |
National Early Warning Score 2 (NEWS2) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Co-existing disease | Â | Â | Â | Â | Â | Conjunctivitis | Thyroid enlargement | Â | Â |
Vital signs abnormality | Pre-Hyper-tension | No | Pre-Hyper-tension | Pre-Hyper-tension | Pre-Hyper-tension | Pre-Hyper-tension | Pre-Hyper-tension | Pre-Hyper-tension | Stage 1 Hyper-tension |
Chest X-ray abnormality | No | Bilateral hilar lymphadenopathy | Left lobe pneumonia | Right lobe pneumonia | No | No | No | No | Aorta dilatation |
Electrocardiography (ECG) abnormality | No | No | No | No | No | No | No | No | No |
Laboratory abnormality | Â | Â | Â | Â | Â | Â | Â | High level of AST/ALT | Â |
Treatment emergent adverse event (TEAE) | Right lobe pneumonia | – | Rash maculo-papular | Blood lactate | – | – | Cutaneous candidiasis, myalgia | Hepato-biliary disorder | – |
Starting day (duration in days) of TEAE | 7* | – | 9 (6) | 3 (Unknown) | – | – | 14 (10; 2) | 0 (> 44) | – |